First Trust Advisors LP raised its stake in shares of Luminex Co. (NASDAQ:LMNX) by 50.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,837 shares of the medical instruments supplier’s stock after buying an additional 8,024 shares during the quarter. First Trust Advisors LP owned about 0.05% of Luminex worth $470,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of LMNX. Crossmark Global Holdings Inc. acquired a new position in shares of Luminex during the 3rd quarter worth about $254,000. BNP Paribas Arbitrage SA grew its position in shares of Luminex by 69.3% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 21,493 shares of the medical instruments supplier’s stock worth $437,000 after buying an additional 8,797 shares during the period. Municipal Employees Retirement System of Michigan grew its position in shares of Luminex by 63.6% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 15,430 shares of the medical instruments supplier’s stock worth $314,000 after buying an additional 6,000 shares during the period. Russell Investments Group Ltd. grew its position in shares of Luminex by 21.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 69,501 shares of the medical instruments supplier’s stock worth $1,413,000 after buying an additional 12,485 shares during the period. Finally, Ameriprise Financial Inc. grew its position in shares of Luminex by 15.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 298,340 shares of the medical instruments supplier’s stock worth $6,065,000 after buying an additional 39,283 shares during the period. Institutional investors own 81.39% of the company’s stock.
Shares of NASDAQ:LMNX opened at $21.07 on Friday. Luminex Co. has a 52-week low of $17.70 and a 52-week high of $22.42. The company has a market capitalization of $929.71, a P/E ratio of 23.15, a price-to-earnings-growth ratio of 2.02 and a beta of 0.16.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 13th. Investors of record on Friday, March 23rd will be given a $0.06 dividend. The ex-dividend date of this dividend is Thursday, March 22nd. This represents a $0.24 annualized dividend and a dividend yield of 1.14%. Luminex’s dividend payout ratio is presently 26.37%.
LMNX has been the subject of several analyst reports. BTIG Research initiated coverage on Luminex in a research report on Friday, January 5th. They set a “buy” rating and a $24.00 target price for the company. BidaskClub upgraded Luminex from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. Finally, William Blair reiterated a “market perform” rating on shares of Luminex in a research report on Tuesday, February 13th. Four equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $22.33.
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.